In preclinical and clinical PCa therapy studies, radionuclides have been linked to antibodies or peptides with affinity to mucin, ganglioside (L6), Lewis Y (Ley), adenocarcinoma-associated antigens, and Prostate Specific Membrane Antigen (PSMA) [20,39,40,41], but PSMA appears the most specific. The gene discussed is FOLH1; the disease is adenocarcinoma.